NKGen doses first patient in Phase 1/2a Alzheimer’s study (NASDAQ:NKGN)
juststock NKGen Biotech (NASDAQ:NKGN) said it has dosed its first patient in a Phase 1/2a study of its cell therapy SNK01 in the treatment of moderate Alzheimer’s disease, AD. The biotech company said the Phase 1 portion of the study…
